

# ORIGINAL

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Feurer, et al.

Application No.: 10/521,538

Group No.: 1624

Filed: 14 January 2005

Examiner: Deepak Rao

For: Novel 2,5-Disubstitued Pyrimidine Derivatives

#### **CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)**

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 10 April 2006

**COMMISSIONER FOR PATENTS** P.O. Box 1450 **ALEXANDRIA, VA 22202** 

## TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BEFORE MAILING DATE OF EITHER A FINAL ACTION OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))

## TIME OF TRANSMITTAL OF ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

- 1. The information disclosure statement transmitted herewith is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but before the mailing date of either
  - (1) a final action under section 1.113 or
  - (2) a notice of allowance under section 1.311 or
  - (3) any other action closing prosecution

whichever occurs first.

### Attorney Docket No. LeA 35 926

#### FEE

2. Applicant elects the option to pay the fee set forth in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under § 1.97(c) (\$180.00).

Fee due \$ 180.00

## **METHOD OF PAYMENT OF FEE**

3. Please charge Account No. 13-3372 in the amount of \$ 180.00. The Commissioner is also authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 42,972

Telephone: (203) 812-6450

Date: 10 April 2006

Susan M. Pellegrino

Attorney for Applicant(s)

Bayer Corporation

400 Morgan Lane

West Haven, CT 06516

Form PTO-1449 O P E U.S. Department of Commerce Patent and Trademark Office	Serial No.	Group Art Unit	Filing Date	Atty. Docket No.
	10/521,538	1624	14 Jan. 2005	LeA 35 926
INFORMATION DISCLOSURE CITATION	Applicant(s) Feu	rer, et al.		

•						FO	REIG	N PA	TENT DOCU	JMENTS				
Examiner Initials	No.		DOCUMENT NO.				DATE COUNTRY	PRIMARY	SUB-	TRANSLATION				
			·						DD/MM/YY	0001(1111	CLASS	CLASS	YES	NO
	F1	9	8	1	6	2	2	3	23/04/98	DE				X
	F2	9	8	1	6	5	0	7	23/04/98	DE				x
	F3	9	8	2	3	6	1	9	04/06/98	DE				x
	F4	0	0	0	6	5	6	7	10/02/00	DE				x
	F5	0	0	0	6	5	6	8	10/02/00	DE				x
	F6	0	0	0	6	5	6	9	10/02/00	DE				х
	F7	0	0	2	1	9	5	4	20/04/00	DE				x
	F8	0	2	0	4	2	2	9	17/01/02	US				
	F9	0	2	0	4	3	0	0	17/01/02	Љ				X
	F10	0	2	0	4	3	0	1	17/01/02	DE				x
	F11	0	2	0	4	3	0	2	17/01/02	US				

<del></del>	 	
EXAMINER		DATE CONSIDERED

<sup>\*</sup> EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OPE 49 0 1 2 7006 W

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitu	te for form 1449/PTO	DEM			Complete if Known				
				Application Number	10/521,538				
INF	ORMATION	DIS	CLOSURE	Filing Date	14 January 2005				
STATEMENT BY APPLICANT				First Named Inventor	Feurer, et al.				
	(Use as many she	ote se n	acaseand	Art Unit	1624				
	Ose as many sne	et3 63 fi	ecessary)	Examiner Name	Deepak Rao				
Sheet	2	of	3	Attorney Docket Number	LeA 35 926				

		NON PATENT LITERATURE DOCUMENTS	
Examiner nitials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	YAMADA, et al., Role of Nitric Oxide and Cyclic GMP in the Dizocilpine-Induced Impairment of Spontaneous Alternation Behavior in Mice, Neuroscience, vol. 74, no. 2, 1996, pp. 365-374	
	R2	WU, et al., YC-1, A Novel Activator of Platelet Guanylate Cyclase, Blood, vol. 84, no. 12, 1994 pp. 4226-4233	
	R3	MÜLSCH, et al., Effect of YC-1, An NO-Independent, Superoxide-Sensitive Stimulator of Soluble Guanylyl Cyclase, On Smooth Muscle Responsiveness to Nitrovasodilators, British Journal of Pharmacy, vol. 120, 1997, pp. 681-689	
-	R4	GOLDBERG, et al., Stimulation of Human Platelet Guanylate Cyclase by Fatty Acids, Journal of Biological Chemistry, vol. 252, no. 4, 1977, pp. 1279-1285	
	R5	PETTIBONE, et al., A Structurally Novel Stimulator of Guanylate Cyclase with Long-Lasting Hypotensive Activity in the Dog, European Journal of Pharmacology, vol. 116, 1985, pp. 307-312	
	R6	YU, et al., Vasorelaxant Effect of Isoliquiritigenin, A Novel Soluble Guanylate Cyclase Activator, In Rat Aorta, British Journal of Pharmacology, vol. 114, 1995, pp. 1587-1594	
	R7	KRAUSE, et al., Improved Procedures for the Palladium-Catalyzed Coupling of Terminal Alkynes with Aryl Bromides (Sonogashira Coupling), Journal of Organic Chemistry, vol. 63, 1998, pp. 8551-8553	
- 10	R8	SUZUKI, Organoborates in New Synthetic Reactions, Accounts of Chemical Research, vol. 15, 1982, pp. 178-184	
	R9	MIYAURA, et al., Palladium-Catalyzed Inter- and Intramolecular Cross-Coupling Reactions of B-Alkyl-9-borabicydo[3.3.1]nonane Derivatives with 1-Halo-1-alkenes or Haloarenes. Syntheses of Functionalized Alkenes, Arenes, and Cycloalkenes via a Hydroboration-Coupling Sequence, Journal of the American Chemical Society, vol. 111,1989, pp. 314-321	
	R10	BUCHWALD, et al., Palladium-catalyzed amination of Aryl halides and Sulfonates, Journal of Organometallic Chemistry, vol. 576, 1999, pp. 125-146	

Examiner     Date	
Signature Consider	ered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

O 1 P E 2000 APR 13 2006

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number 10/521,538

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Filing Date 14 January 2005

First Named Inventor Feurer et al.

Art Unit 1624

STATEMENT BY APPLICANT

(Use as many sheets as necessary)

First Named Inventor Feurer et al.

Art Unit 1624

Examiner Name Deepak Rao

Sheet 3 of 3 Attorney Docket Number LeA 35 926

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
	R11	STILLE, Palladium-katalysierte Kupplungsreaktionen Organischer Elektrophile mit Organozinn-Verbindungen, Angew. Chem., vol. 98, 1986, pp.504-519					
			•				
		·					

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.